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The neuropeptides orexin A and orexin B, produced in hypothalamic neurons, are 
critical regulators of sleep/wake states. Deficiency of orexin-signaling results in 
narcoleptic phenotype in humans, dogs, and rodents. Recently, accumulating evidence 
has indicated that the orexin system regulates sleep and wakefulness through 
interactions with neuronal systems that are closely related with emotion, reward, and 
energy homeostasis. In this review, we will discuss the current understanding of the 
physiology of the orexin system especially focusing on its roles in the regulation of 
sleep/wakefulness states. 
 




Orexin was first identified as endogenous peptide ligands for two orphan G-protein 
coupled receptors in 19981. They were initially recognized as regulators of feeding 
behavior, firstly because of their exclusive production in the lateral hypothalamic area 
(LHA), a region known as the feeding center, and secondly owing to their 
pharmacological activity. 1-4  Subsequently, this peptide system was shown to be a 
critical regulator of sleep/wake states. Since then, this and other groups have been 
using a multidisciplinary approach to understand various aspects of the physiological 
roles of orexin peptides, and have uncovered crucial roles of the orexin system in the 
regulatory mechanisms in sleep/wake states, energy homeostasis, and the reward 
systems. Especially, the finding that an orexin deficiency causes narcolepsy in humans 
and other animals has had a huge impact on the studies of sleep and wakefulness and 
other areas.5-9 Recent studies of orexin-producing neurons’ efferent and afferent 
systems have suggested further roles for orexin in the coordination of emotion, energy 
homeostasis, reward and arousal.10-17 These findings suggest that orexin neurons are 
involved in sensing the body’s external and internal environments, and regulate 
sleep/wake states accordingly, which is beneficial for survival. This review will 
discuss the mechanisms by which the orexin system regulates sleep/wake states, and 




Orexin and orexin receptors 
Orexins were identified by a strategy called reverse pharmacology. There are over 100 
of G-protein coupled receptors (GPCRs) whose ligands are still unknown and are 
therefore, referred to as orphan GPCRs. Many of these orphan GPCRs are likely to be 
receptors for heretofore unidentified signaling molecules, including new peptide 
hormones and neuropeptides. In 1998, during searching for endogenous ligands for 
various orphan GPCRs, our group identified orexin A and orexin B as endogenous 
ligands for two related orphan GPCRs.1 Because these peptides were localized in the 
LHA, and intracerebroventricular (ICV) injection of them in rats or mice acutely 
increased food consumption, they were named orexin A and B after the Greek word 
‘orexis’, meaning appetite. Orexin A and -B are produced by cleavage of a common 
precursor polypeptide, prepro-orexin. The primary structure of orexin A predicted 
from the cDNA sequences is completely conserved among several mammalian species 
(human, rat, mouse, cow, sheep, dog and pig). On the other hand, rat orexin B is a 28-
amino-acid, C-terminally amidated linear peptide of 2937 Da, which is 46% (13/28) 
identical in sequence to orexin A. The C-terminal half of orexin B is very similar to 
that of orexin A (73%; 11/15), while the N-terminal half is variable. Orexin B also has 
a high degree of sequence similarity among species. Several study revealed that the 
structures of fish, xenopus, and chicken orexin A and orexin B have also conserved 
structures as compared with mammalian sequences(Figure 1).18-20  Furthermore, 
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several studies have shown that orexins play roles in regulation  of food intake and 
sleep/wake behavior in goldfishes and zebrafishes. 21-24 These observations suggest 
that structures and functions of orexins are phyllognetically well conserved. 
As an independent work, de Lecea et al. identified mRNA expressed 
specifically within the hypothalamus and identified a cDNA encoding a polypeptide 
identical to prepro-orexin, and named the putative mature peptides hypocretin-1 and -
2 (Hcrt-1 and Hcrt-2).25 The terms ‘orexin’ and ‘hypocretin’ are used as synonyms in 
many papers currently. 
 In mammals, the actions of orexins are mediated by two GPCRs, named 
orexin 1 (OX1R) and orexin 2 (OX2R) receptors (also named as HCRTR1 and 
HCRTR2). OX1R has one-order higher affinity for orexin A than orexin B, while 
OX2R binds orexin A and orexin B with similar affinities. OX1R couples to the Gq/11 
subclass of heterotrimeric G proteins, while OX2R couples to Gq/11 or Gi/o in a 
neuronal cell line in culture. 26 
 Orexin-expressing neurons (orexin neurons) are distributed within the lateral 
hypothalamic area (LHA) and posterior hypothalamus (PH).1, 27-29 The number of 
these neurons has been estimated around 3000 in rat and 50000 in human brains. 
Although their cell bodies are exclusively localized in the hypothalamus, orexin 
neurons send their axonal projections diffusely throughout the central nervous system 
(CNS), excluding the cerebellum. Especially dense projections are found in the 
hypothalamus (such as the arcuate nucleus (ARC) and tuberomammillary nucleus 
(TMN)), and the brain stem (such as the central gray, locus coeruleus (LC), and raphe 
nuclei).27-29 Consistent with the broad projections of orexin neurons, OX1R and OX2R 
mRNAs show wide distributions in the CNS with partly overlapping but distinct 
patterns.30  For instance, nuclei such as the LC and ventral tegmental area (VTA) 
mainly express OX1R mRNA, while those including the TMN, nucleus accumbens 
(NAc), and septal nuclei mainly express OX2R mRNA. Both mRNAs are observed in 
the raphe nuclei, laterodorsal tegmental nucleus (LDT), and pedunculopontine 
tegmental nucleus (PPT). These distributions of both receptor mRNAs suggest partly 
overlapping and partly distinct roles of orexin receptors. 
 
Narcolepsy  
 In 1999, two independent studies utilizing dog forward genetics and mouse reverse 
genetics clearly showed a causal linkage between disruption of the orexin system and 
narcolepsy-cataplexy. Subsequently, several studies established that loss of orexin 
neurons is accompanied by human narcolepsy patients. The symptoms and 
pathophysiology of the sleep disorder narcolepsy, caused by an orexin deficiency, 
provide insight into the physiological roles of orexin.5-8 Therefore, we will briefly 
mention about this disorder in this section. 
Human narcolepsy is a debilitating neurological disorder that affects 
approximately 1 in 2000 individuals in the U.S.31 Onset of the condition is usually 
during adolescence. A cardinal symptom of the disorder is excessive daytime 
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sleepiness (an insurmountable urge to sleep), which manifests itself primarily when 
the subject falls asleep at inappropriate times (“sleep attacks”). When normal 
individuals fall asleep, a certain period of non-REM (NREM) sleep (60-90 minutes) 
usually precedes REM sleep. However, the latency of rapid eye movement (REM) 
sleep is markedly reduced in narcolepsy patients, and REM sleeps are sometimes 
observed immediately after wakefulness (sleep-onset REM). The existence of “sleep-
onset REM” periods is one of the important diagnostic criteria for narcolepsy. In 
patients, nocturnal sleep is also disturbed and is often accompanied by hypnagogic 
hallucinations, vivid dreaming, and sleep paralysis, which usually occur when they 
fall asleep.  
Narcolepsy patients often suffer from attacks called “cataplexy”, which is a 
sudden weakening of bilateral muscle tone (muscle atonia), ranging from jaw 
dropping and speech slurring to complete bilateral collapse of the postural muscles. 
These attacks are often triggered by emotional stimuli, such as laughter, excitement, 
and pleasure. Narcolepsy which is accompanied with cataplexy is sometimes referred 
as “narcolepsy-cataplexy”. 
Symptoms of narcolepsy-cataplexy can be divided into two distinct 
pathological phenomena. One is an inability to maintain a consolidated waking period, 
characterized by abrupt transitions from wakefulness to NREM sleep (i.e. 
dysregulation of NREM sleep onset). This phenomenon manifests as excessive 
daytime sleepiness or a sleep attack. This symptom is treated by psychostimulants, 
such as methylphenidate, methamphetamine, and modafinil. The other key 
phenomenon is the pathological intrusion of REM sleep into wakefulness (i.e. 
dysregulation of REM sleep onset): it is during these periods that patients may 
experience cataplexy, hypnagogic hallucinations and sleep paralysis. These symptoms 
are treated by tricyclic depressants and selective serotonin re-uptake inhibitors.  
Collectively, this disorder is characterized by the inability to maintain each 
vigilance state, pathological intrusion of non-REM and/or REM sleep into 
wakefulness, and frequent transitions between states of sleep and wakefulness. This 
suggests that orexins have important physiological roles in the maintenance and 
stabilization of sleep and wakefulness. 
 
Orexin or orexin receptor-2 deficiencies cause narcoleptic phenotype 
The first clues towards an involvement of the orexins in narcolepsy came from animal 
models; mice lacking the orexin gene or dogs with null mutations in the orexin 
receptor-2 (OX2R) gene show phenotypes remarkably similar to humans with 
narcolepsy.7, 8 Orexin knockout mice (orexin-/- mice) exhibit frequent sudden collapses 
that resemble human cataplexy attacks during the dark phase, when mice spend the 
most time awake and active.7 These attacks are thought to be homologous to 
cataplexy.32 Quantitative sleep state parameters of orexin-/- mice revealed slightly 
decreased waking time, increased REM sleep time during dark period, decreased 
REM sleep latency, and, most importantly, a markedly decreased duration of wake 
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time during the dark phase (i.e. inability to maintain a long awake period). Dogs with 
null mutations in the orexin receptor-2 (OX2R) gene show phenotypes remarkably 
similar to humans with narcolepsy.7, 8 
The link between orexin dysfunction and narcolepsy, especially which 
accompanied with cataplexy (narcolepsy-cataplexy), has since been supported by 
studies with human patients. In contrast to normal control individuals, the vast 
majority of narcoleptic individuals have low or undetectable levels of orexin A in the 
cerebrospinal fluid (CSF).33 (In CSF, orexin B is not detectable even in healthy 
individuals.) A postmortem study of human narcolepsy subjects showed undetectable 
levels of orexin peptides in the cortex and pons, and an 80-100% reduction in the 
number of neurons containing detectable prepro-orexin mRNA or orexin-like 
immunoreactivity in the hypothalamus.5, 6 No mutation has been found either in the 
prepro-orexin or orexin receptor genes of human narcolepsy-cataplexy patients, 
except for an unusually severe, early onset case associated with a mutation in the 
signal peptide of prepro-orexin that impairs peptide trafficking and processing.5 In 
this case, abnormal signal sequence cleavage results in accumulation of abnormal 
orexin peptide in cells leading cell death. A recent finding showing concomitant loss 
of dynorphin, neuronal activity-regulated pentraxin, and orexin, which colocalize in 
orexin neurons, further suggests a loss of functional orexin neurons, rather than the 
selective inhibition of orexin expression, in narcolepsy-cataplexy.34 Based on these 
observations, as well as a strong association of human narcolepsy-cataplexy with 
certain HLA alleles,35 it has been speculated that narcolepsy-cataplexy may result 
from selective autoimmune degeneration of orexin neurons. Regardless of the cause 
of the neuron loss, the orexin signaling deficiency in narcolepsy-cataplexy shows that 
this neuropeptide system plays an important role in the regulation of sleep and 
wakefulness, especially in the maintenance of long, consolidated awake periods. 
We produced transgenic mice in which orexin neurons are ablated by 
expression of a N-terminally truncated ataxin-3, which induces post-natal apoptotic 
death of all orexin neurons by adulthood (orexin neuron-ablated mice).9  Adult mice 
show essentially the same phenotype of sleep/wake regulation as orexin-/- mice. 
Therefore, although orexin neurons produce other neurotransmitters such as glutamate 
and dynorphin,36-38 orexin is the most important factor among them for regulation of 
sleep/wake states by these neurons.  
Regarding the contribution of each receptor, OX2R-/- mice have characteristics 
of narcolepsy-cataplexy, although their narcoleptic phenotype is less severe than that 
found in orexin-/- mice.39, 40 They show behavioral arrests that are less frequent and 
severe than those of orexin-/- mice. OX1R-/- mice do not have overt behavioral 
abnormalities. OX1R-/-;OX2R-/- mice appear to be a phenocopy of orexin knockout 
mice,41 implying that these two receptors are sufficient to mediate regulation of 
sleep/wake by orexins. These observations also suggest that despite the lack of an 
overt OX1R-/- phenotype, loss of signaling through both receptor pathways appears to 
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be necessary for the emergence of a complete narcoleptic phenotype, suggesting that 
both receptors are involved in the regulation of sleep and wakefulness. 
 
 
Therapeutic potentials of orexin agonists and antagonists 
The finding of low orexin A levels in CSF in patients with narcolepsy-cataplexy led to 
the development of a novel, definitive diagnostic test for this disease.33 A low orexin 
A levels in CSF has been used as one of the diagnostic criteria for narcolepsy-
cataplexy according to the 2nd edition of the international classification of sleep 
disorders.42 
Moreover, the discovery of causal link between loss of orexin signaling and 
human narcolepsy-cataplexy has brought about a possibility of novel therapies for this 
disease. Currently, excessive sleepiness in narcolepsy is treated using 
psychostimulants, while cataplexy is treated with tricyclic antidepressants. γ-
hydroxybutyrate (sodium oxybate) is also used to consolidate nocturnal sleep and 
reduce cataplexy.43 Treatment with these compounds are problematic due to limited 
effectiveness, undesirable side effects such as insomnia or symptom rebounds, and the 
potential for abuse. Since orexin neuron-ablated mice (orexin/ataxin-3 mice) have an 
etiology and course of disease similar to those of human narcolepsy-cataplexy, these 
mice may represent the most accurate pathophysiological model of narcolepsy-
cataplexy available.9 We demonstrated rescue of the narcoleptic phenotype of these 
mice by genetic and pharmacological means.44 Chronic overproduction of orexin 
peptides from an ectopically expressed transgene prevented development of 
narcolepsy syndrome in orexin neuron-ablated mice. Acute ICV administration of 
orexin A also maintained wakefulness, suppressed sleep, and inhibited cataplectic 
attacks in these mice. Intriguingly, ICV administration of orexin A had stronger 
arousal effects in orexin neuron-ablated mice than in wild-type controls, suggesting 
that responsiveness of effecter sites for orexins remains intact, or even more 
responsible for orexins in narcoleptics. These results also indicate that a spatially 
targeted secretion of orexin is not necessary to prevent narcoleptic symptoms. 
Unfortunately, however, constitutive production of orexin peptides from a prepro-
orexin transgene in mice per se caused fragmentation of NREM sleep episodes in the 
light period; when mice spend the most time asleep (our unpublished observations). 
These results indicate that orexin neurons should be turned on and switched off to 
maintain consolidated wakefulness and NREM sleep, respectively. These also suggest 
that orexin receptor agonists with relatively short half-lives (several hours) would be 
of potential value for treating human narcolepsy-cataplexy. Such agonists might also 
be useful in the treatment of other conditions of excessive daytime sleepiness in 
humans.  
Conversely, orexin receptor antagonists might be useful for treatment of 
insomnia patients or as a sleep-inducer. Indeed, Almorexant, an orally available 
antagonist for OX1R and OX2R, has been reported to cause subjective and objective 
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Neural mechanisms of sleep/wake regulation by orexins  
Wakefulness is maintained by multiple neurotransmitters and neuronal pathways. 
Included in this system are monoaminergic and cholinergic neurons reside in the brain 
stem. Monoaminergic neurons, including LC noradrenergic, raphe serotonergic, and 
TMN histaminergic neurons, project diffusely to the forebrain promoting arousal. 
Other important wake-inducing signals are cholinergic neurons in the brain stem and 
project to key forebrain targets such as the thalamus, an area critical to regulating 
cortical activity.46 Monoaminergic neurons are firing at rapid rates during wakefulness, 
while they reduce their activities during NREM sleep and almost cease discharge 
during REM sleep. A subset of PPT/LDT neurons is active during both wakefulness 
and REM sleep (W-REM on), regulating activity of thalamo-cortical projections to 
generate EEG desynchronization characteristics of wakefulness and REM sleep. 
Others are active exclusively during REM sleep (REM-on) and thought to induce 
REM sleep and REM atonia.  Conversely, GABA/galaninergic neurons in the 
ventrolateral preoptic nucleus (VLPO) of the hypothalamus are active during sleep, 
especially non-REM sleep,45 and thought to initiate and maintain NREM sleep. VLPO 
neurons and monoaminergic neurons reciprocally inhibit each other. This reciprocal 
interaction of wake center and sleep center  maintains states of sleep and wakefulness. 
As mentioned above, orexin neurons send dense projections to the 
monoaminergic/cholinergic nuclei involved in sleep/wake regulation (Fig. 2, 3). The 
distribution of the orexin receptors mRNA is consistent with these projection sites; 
within the brain, OX1R is most abundantly expressed in the LC, while OX2R is highly 
expressed in the TMN,30 and both mRNAs are detectable in the raphe nuclei, 
PPT/LDT and BF.  
ICV administration of orexin A in rodents potently reduces REM and non-
REM sleep, and increases wakefulness.47 Application of orexin directly into the LC, 
TMN, LDT, and the lateral preoptic area has effects similar to ICV injection on 
sleep/wake states.48-52  In vitro slice electrophysiology studies has shown that orexin 
increases firing rates of monoaminergic neurons in the LC,53, 54 raphe,55, 56 TMN,57-59 
and cholinergic neurons in the BF and LDT,60, 61 but have no effect on the GABAergic 
neurons in the VLPO.60 A work using cats showed that orexin A inhibits cholinergic 
neurons in the PPT in vivo through activation of GABAergic interneurons and 
GABAergic neurons in the substantia nigra pars reticulata.62 These results indicate 
that orexin neurons affect the activity of PPT/LDT cholinergic neurons both directly 
and indirectly to regulate arousal and REM sleep.  
More recently, Adamantidis et al. succeeded to demonstrate that direct and 
selective photostimulation of orexin neurons in freely moving mice, in which orexin 
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neurons were genetically targeted to express a photo-activatable cation channel 
(channelrhodopsin-2), increased the probability of transition to wakefulness from 
either NREM or REM sleep. 63  
 
 
Regulatory mechanisms and input systems of orexin neurons 
Considering symptoms of narcolepsy-cataplexy, orexin neurons are expected to be 
active during wakefulness and to be silent during sleep. In fact, transgenic mice with 
constitutive activation of orexinergic tone (CAG/orexin mice), in which orexin is 
expressed in a diffuse, ectopic pattern in the brain in unregulated fashion,44 exhibited 
abnormal sleep and wakefulness patterns, including fragmented NREM sleep in the 
light period and incomplete REM sleep atonia with abnormal myoclonic activity 
during REM sleep (our unpublished results). These suggest that orexin neurons need 
to be switched off to maintain consolidated NREM sleep and the muscle atonia that 
accompanies REM sleep.  
Fos expression in orexin neurons in rats is higher during the dark phase (active 
period) than during light phase (rest period).64 Consistently, orexin levels in CSF peak 
during the dark period and decrease during the light period.65 In vivo extracellular 
recordings further confirmed activity patterns of orexin neurons across sleep/wake 
cycles with high temporal resolutions.66-68 Essentially, orexin neurons fired most 
actively during active waking, decreased discharge during quiet waking, were 
virtually silent during NREM sleep, and almost silent but exhibited occasional firing 
during REM sleep.  
How these regulations could be achieved? Orexin neurons receive projections 
from nuclei involved in sleep/wake regulation. GABAergic neurons in the preoptic 
area, including the VLPO, densely innervate orexin neurons (Fig. 3).14, 15 Orexin 
neurons are strongly inhibited by both GABAA receptor agonist, muscimol, and 
GABAB receptor agonist, baclofen.11, 69, 70 Orexin neurons are also innervated by BF 
cholinergic neurons.14 Carbachol, a cholinergic agonist, activates a subset of orexin 
neurons.14, 71 Thus, orexin neurons are likely to be inhibited by sleep-promoting 
neurons and activated by wake-promoting BF neurons: these regulations of orexin 
neurons are in consistent with their proposed function to stabilize wakefulness.  
In contrast, wake-active serotonergic neurons and noradrenergic neurons in the 
brain stem send inhibitory projection to orexin neurons.14, 72, 73 Serotonergic and 
noradrenergic inputs hyperpolarize orexin neurons through activation of G-protein-
regulated inwardly rectifying K+ (GIRK or Kir3) channels mediated by 5-HT1A 
receptors and 2-adrenoceptors, respectively.72, 73 These negative feedback 
mechanisms may also be important for fine adjustment of orexin neuronal activity to 
stabilize wakefulness. Notably, histamine has little effect on orexin neurons.74 
Local interneurons may also play important roles in the regulation of orexin 
neurons. In slice preparations, orexin A and orexin B were reported to depolarize 
orexin neurons.69 This effect appears to be medicated by orexin-mediated excitation of 
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local glutamatergic neurons that regulate orexin neuronal activity, in part by 
presynaptic facilitation of glutamate release. On the other hand, GABAergic input 
from local interneurons to orexin neurons is also important for organization of orexin 
neuronal activity.75 Genetic disruption of GABAB input resulted in marked sleep/wake 
abnormality.75 
 Horvath and Gao reported an unusual synaptic organization on orexin neurons 
in which excitatory synaptic currents and asymmetric synapses exert control on the 
perikarya of these long-projective neurons with minimal inhibitory input, which is 
sharp contrast to the fact that neuronal cell bodies in the central nervous system are 
either dominated by inhibitory inputs (long-projection neurons), or have an 
approximate ratio of excitatory to inhibitory inputs of 1:1.76 This unique input 
organization of orexin neurons may be a necessary element for the maintenance of a 
low threshold for arousal and alertness. On the other hand, this circuitry, along with 
abundant input from the limbic system, may also be an underlying cause of insomnia. 
Consistent with these results, an electrophysiological study with slice preparations 
indicated that orexin neurons are tonically activated by glutamatergic neurons,69 while 
basal tone of GABAergic input seems to be low, because GABA antagonists do not 
influence basal activity of orexin neurons. However, in slice from mice with selective 
deletion of GABAB receptor in orexin neurons (oxGKO mice), orexin neurons 
responded with depolarization to bicuculline application. This indicates that GABAA 
receptors are tonically activated in orexin neurons of these mice. As a consequence, 
orexin neurons in these mice showed decreased responsiveness to both excitatory and 
inhibitory inputs as compared with wild type mice.75 With the observation showing 
that oxGKO mice had highly fragmented sleep/wake state, these observations suggest 
that proper local GABAergic regulation and normal synaptic organization of orexin 
neurons are highly important for sleep/wake regulation. 
 
  
Orexin neurons as a stabilizer of sleep/wake states 
How do the orexins physiologically regulate sleep and wakefulness, and why does a 
lack of orexin signaling result in narcolepsy, a disorder characterized by instability of 
wakefulness? As mentioned above, orexin neurons, monoaminergic/cholinergic 
centers in the brain stem, and the sleep-active VLPO neurons constitute a triangular 
interaction; orexin neurons send excitatory projections to monoaminergic neurons, 
and these monoaminergic neurons send inhibitory projections back to orexin neurons. 
VLPO sleep-active neurons send inhibitory projections to both monoaminergic 
neurons and orexin neurons. Monoaminergic neurons send inhibitory projections to 
VLPO sleep-active neurons. This triangular organization seems to be highly important 
for stability of vigilance states.  VLPO sleep-active neurons and monoaminergic 
neurons inhibit each other. This reciprocal inhibition is well suited to avoid 
intermediate states. Orexin neurons can stabilize waking state by enhancing activity of 
monoaminergic neurons during wakefulness, avoiding state instability caused by 
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small perturbations. At the same time, negative feedback input to orexin neurons from 
serotonergic and noradrenergic neurons work to maintain the activities of orexin and 
monoaminergic neurons within appropriate ranges. During sleep, orexin neurons are 
turned off together with monoaminergic neurons by VLPO GABA/galaninergic 
neurons. 
 In narcoleptics, the orexin-target neurons, such as monoaminergic neurons in 
the brain stem, might undergo changes in their synaptic organization through 
plasticity or synaptic scaling mechanisms due to chronic deficiency of orexins. These 
changes might help the monoaminergic cells to be activated without orexins. 
Simultaneously, this mechanism may set up a “flip-flop” circuit between Sleep-active 
VLPO neurons and wake-active monoaminergic neurons;46 these two components 
reciprocally inhibit each other. In this type of mutually-inhibitory circuits, when 
activity on either side begins to overcome the other, the system will flip into one of 
two possible extremes. A small perturbation on the activity of one side can easily 
cause abrupt switching between two states, resulting in frequent state transitions, 
fundamental problems seen in narcolepsy.  
The fact described earlier that orexin neurons are much more active during 
active waking than during quiet waking in vivo clearly suggest roles of orexin go 
beyond mere global arousal. Recently, Deadwyler et al. reported that systemic and 
nasal delivery of orexin A reduced the effects of sleep deprivation on cognitive 
performance in nonhuman primates; interestingly, orexin A did not produce 
facilitative effects if the animals were not sleep deprived,77 although it is not clear 
whether orexin A penetrates the blood-brain barrier, or orexin A can influence 
vigilance states by acting on peripheral receptors. In slice preparations from rat 
prefrontal cortex, orexin was reported to induce calcium transients in single spines 
postsynaptic to identified thalamocortical boutons.78, 79 By this cellular mechanism, 
orexinergic projections to the prefrontal cortex may play a role in prefrontal or 




Roles of orexin in other functions 
Orexins are thought to be also involved in many other functions, including feeding 
behavior, autonomic regulation, endocrine functions, nociception, reward system and 
emotion. All these systems should be well coordinated. Sleep and wakefulness are 
regulated to occur at appropriate times that are in accordance with our internal and 
external environments.  Avoiding danger and finding food, which are life-essential 
activities that are regulated by emotion, reward and energy balance, require vigilance 
and thus, by definition, wakefulness.  The orexin system regulates sleep and 




Reciprocal connections between the orexin system and multiple neuronal 
systems indicate that orexin neurons provide crucial links between multiple brain 
functions, such as energy homeostasis, reward system, emotion, and arousal. Future 
studies with full use of mouse molecular genetics, such as selective deletions of genes 
for particular receptor or signaling molecule in orexin neurons, would lead to further 
understanding of integrative physiology orchestrated by the orexin system. 
From clinical perspective, discovery of the linkage between the orexin system 
and human narcolepsy-cataplexy led to the development of a novel diagnosis of this 
disease and to the expectation for development of novel drugs for treatment of 
narcolepsy-cataplexy. Moreover, future studies may let us understand why orexin 
neurons degenerate in narcolepsy-cataplexy patients, which would lead to more 
fundamental therapies for narcolepsy-cataplexy. 
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Fig. 1. An overview of orexin system. 
(A) Structure of mature orexin A and orexin B peptides. The topology of the two-
intrachain bonds in orexin A is indicated above the sequence. Shadows indicate amino 
acid identity. Mammalian orexin A sequences thus far identified (human, rat, mouse, 
pig, dog, sheep, and cow) are all identical, while the sequences of orexin B show 
some differences among species. 
(B) Orexins and their receptors. Orexin A and orexin B are derived from a common 
precursor peptide, prepro-orexin. The actions of orexins are mediated via two G 
protein-coupled receptors named orexin-1 (OX1R) and orexin-2 (OX2R) receptors. 
OX1R is selective for orexin A, whereas OX2R is a nonselective receptor for both 
orexin A and orexin B. OX1R is coupled exclusively to the Gq subclass of 
heterotrimeric G proteins, whereas OX2R couples to Gi/o and /or Gq. 
 
Fig. 2. Schematic drawing of main axonal projections of orexin neurons and 
distribution of orexin receptors in brain. 
This figure summarizes predicted orexinergic projections in the human brain. Please 
note that distributions of orexin fibres and receptors (OX1R, OX2R) are predicted 
from the results of studies on rodent brains, because it is on rats or mice that most 
histological studies on the orexin system have been carried out. Circles show regions 
with strong receptor expression and dense orexinergic projections. Orexin neurons 
originating in the lateral hypothalamic area (LHA) and posterior hypothalamus (PH) 
regulate sleep and wakefulness and the maintenance of wakefulness by sending 
excitatory projections to the entire CNS, excluding the cerebellum, with particularly 
dense projections to monoaminergic and cholinergic nuclei in the brain stem and 
hypothalamic regions, including the locus coeruleus (LC, containing noradrenaline), 
tuberomammillary nucleus (TMN, containing histamine), raphe nuclei (Raphe, 
containing serotonin) and laterodorsal/pedunclopontine tegmental nuclei (LDT/PPT), 
containing acetylcholine). Orexin neurons also have links with the reward system 
through the ventral tegmental area (VTA, containing dopamine) and with the 
hypothalamic nuclei that stimulate feeding behaviour. This figure is adapted with 
modification from80.  
 
Fig.3. Interactions between orexin neurons with other brain regions.  
Orexin neurons in the lateral hypothalamic area (LHA) and posterior hypothalamus 
(PH) are anatomically well placed to provide a link between the limbic system, 
systems involved in energy homeostasis and monoaminergic and cholinergic neurons 
in the brain stem. Solid arrows show excitatory projections and broken lines inhibitory 
ones. Wake-active regions, sleep-active regions and REM-active regions are shown by 
red, blue and green boxes, respectively. Orexin neurons promote wakefulness through 
the monoaminergic nuclei that are wake-active. Stimulation of dopaminergic centres 
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by orexins can modulate reward systems (purple). Peripheral metabolic signals such 
as leptin, ghrelin and glucose influence orexin neuronal activity to coordinate arousal 
and energy homeostasis. The nucleus suprachiasmaticus (SCN), the central body 
clock, may send signals to orexin neurons via the dorsomedial hypothalamus (DMH). 
Input from the limbic system (amygdala and bed nucleus of the stria terminalis (BST)) 
might regulate the activity of orexin neurons upon emotional stimuli to evoke 
emotional arousal or fear-related responses. VLPO, ventrolateral preoptic area; DR, 
dorsal raphe; GABA, γ-aminobutyric acid; LC, locus coeruleus; LDT, laterodorsal 
tegmental nucleus; PPT, pedunculopontine tegmental nucleus; SNr, substantia nigra 
pars reticulata; TMN, tuberomammillary nucleus. 
This figure is adapted with modification from80. 
 
 
Fig. 4. Mechanisms by which the orexin system stabilizes sleep /wake states. 
The figures represent functional interactions between orexin neurons, monoaminergic 
wake-active centres and the ventrolateral preoptic area (VLPO) sleep-active centre. 
Solid arrows show excitatory input, and broken lines inhibitory input. The thickness 
of arrows and lines represents the relative strength of excitatory and inhibitory input, 
respectively. Circle sizes represent relative activities of each region. (a) Awake state. 
Orexin neurons send excitatory influences to monoaminergic neurons, which send 
inhibitory feedback projections to orexin neurons. This feedback mechanism might 
maintain the activity of monoaminergic neurons. A slight decrease in input to the 
monoaminergic neurons results in decreased inhibitory influence to orexin neurons. 
Orexin neurons, therefore, are disinhibited and increase excitatory influence to 
monoaminergic cells to maintain their activity. These monoaminergic cells send 
excitatory projections to the thalamus and cerebral cortex, and send inhibitory 
projections to the VLPO sleep centre. These mechanisms maintain wakefulness states. 
(b) Sleep state. VLPO sleep-active neurons are activated and send inhibitory 
projections to monoaminergic neurons and orexin neurons to maintain sleep. (c) 
Narcolepsy. If orexin neurons are removed, monoaminergic neurons and VLPO 
neurons set up a mutually inhibitory circuit, which can cause unwanted and abrupt 
transitions between the states. Activity in one of the competing sides shuts down 
inhibitory inputs from the other side, and therefore disinhibits its own action. So, 
when either side begins to overcome the other, the switch abruptly turns into the 
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